We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

About Prescription Drugs: Top 300

★★★★★ Everything you need to know about the top 300 most-prescribed drugs.

Learning essential information about the top 300 prescription drugs doesn’t have to be tedious. With Prescription Drug Cards: Top 300, you’ll get a comprehensive, easy-to-use study tool that will tell you everything you need to know about these most-prescribed drugs. And as a bonus, you’ll get the top 100 non-prescription drugs, too. This tool is ready to go with quick image and information retrieval—no Internet connection necessary!

Features:

You’ll learn crucial information about the top 300 prescription drugs, including:

✓ Generic and common name

✓ Class

✓ Dosage Forms

✓ Approved Dose and Indications

✓ Off-Label Use

✓ Contraindications

✓ Adverse Reactions

✓ Drug Interactions

✓ Monitoring Parameters

✓ Medication Safety Issues and Black Box Warnings

Learn vital drug information: Download Prescription Drug Cards: Top 300!

What's New in the Latest Version 4.70.2291

Last updated on May 16, 2017

This version includes a few improvements to make your study experience smoother.

Let us know what you think by emailing us at [email protected] or by leaving a 5-star review.

Translation Loading...

Additional APP Information

Latest Version

Request Prescription Drugs: Top 300 Update 4.70.2291

Uploaded by

Marvin Guerrero Fernandez

Requires Android

Android 5.0+

Show More

Prescription Drugs: Top 300 Screenshots

Also available for other platforms

Languages
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.